TABLE 3

Risks and benefits of SGLT-2 inhibitors

	Benefits					Risks
	Hemoglobin A1c	Weight and blood pressure	Heart failure hospitalizations	Cardiovascular events	Progression of renal disease	Fracture, amputation	Genital infection
Empagliflozin	Decrease	Decrease	Decrease	Decrease	Decrease	No change	Increase
Canagliflozin	Decrease	Decrease	Decrease	No change	Decrease	No change^a	Increase
Dapagliflozin	Decrease	Decrease	Decrease	No change	Decrease	No change	Increase
Ertugliflozin	Decrease	Decrease	Decrease	No change	No change	No change	Increase

↵a Changed from “increases risk” to “no change” after the removal of the black box warning by the US Food and Drug Administration.